Design Therapeutics (DSGN) Stock Price, News & Analysis

Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $5.47 to $5.65
• 50-Day Range: $4.56 to $7.50
• 52-Week Range: $2.13 to $7.77
• Volume: 4,235 shs
• Average Volume: 239,075 shs
• Market Capitalization: $314.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Design Therapeutics Stock Analysis - MarketRank™

Design Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 765th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Design Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Design Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Design Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Design Therapeutics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Design Therapeutics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Design Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.07% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Design Therapeutics has recently decreased by 1.15%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Design Therapeutics does not currently pay a dividend.

Dividend Growth

Design Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.07% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Design Therapeutics has recently decreased by 1.15%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Design Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

Search Interest

2 people have searched for DSGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Design Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DSGN Stock Analysis - Frequently Asked Questions

How have DSGN shares performed this year?

Design Therapeutics' stock was trading at $2.65 on January 1st, 2024. Since then, DSGN stock has increased by 106.8% and is now trading at $5.48.
View the best growth stocks for 2024 here.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) posted its quarterly earnings data on Monday, August, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02.

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' top institutional shareholders include Frazier Life Sciences Management L.P. (3.34%), Baker BROS. Advisors LP (3.08%), Point72 Asset Management L.P. (2.83%) and FMR LLC (1.46%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad, Stella Xu and Arsani William.
View institutional ownership trends.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Design Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Design Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DSGN
• CUSIP: N/A
• CIK: 1807120
• Web: www.designtx.com
• Phone: 858-293-4900
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +27.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-66,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -18.01%
• Return on Assets: -17.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 34.61
• Quick Ratio: 34.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.46 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 56,620,000
• Free Float: 38,955,000
• Market Cap: $310.28 million
• Optionable: Optionable
• Beta: 1.83